- Home
- NXL vs FTHM Comparison
NXL vs FTHM Comparison
Compare NXL & FTHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- FTHM
- Stock Information
- Founded
- NXL 2010
- FTHM 2010
- Country
- NXL United States
- FTHM United States
- Employees
- NXL N/A
- FTHM N/A
- Industry
- NXL Medical Specialities
- FTHM Real Estate
- Sector
- NXL Health Care
- FTHM Finance
- Exchange
- NXL Nasdaq
- FTHM Nasdaq
- Market Cap
- NXL 24.2M
- FTHM 21.0M
- IPO Year
- NXL 2022
- FTHM 2020
- Fundamental
- Price
- NXL $1.17
- FTHM $0.87
- Analyst Decision
- NXL Strong Buy
- FTHM Strong Buy
- Analyst Count
- NXL 1
- FTHM 4
- Target Price
- NXL $5.00
- FTHM $4.25
- AVG Volume (30 Days)
- NXL 121.2K
- FTHM 29.9K
- Earning Date
- NXL 05-20-2025
- FTHM 05-13-2025
- Dividend Yield
- NXL N/A
- FTHM N/A
- EPS Growth
- NXL N/A
- FTHM N/A
- EPS
- NXL N/A
- FTHM N/A
- Revenue
- NXL $168,721.00
- FTHM $335,184,000.00
- Revenue This Year
- NXL $79.59
- FTHM $29.10
- Revenue Next Year
- NXL $334.65
- FTHM $20.74
- P/E Ratio
- NXL N/A
- FTHM N/A
- Revenue Growth
- NXL 52.35
- FTHM N/A
- 52 Week Low
- NXL $0.53
- FTHM $0.65
- 52 Week High
- NXL $4.49
- FTHM $3.37
- Technical
- Relative Strength Index (RSI)
- NXL 22.27
- FTHM 58.62
- Support Level
- NXL $1.75
- FTHM $0.77
- Resistance Level
- NXL $1.39
- FTHM $0.92
- Average True Range (ATR)
- NXL 0.13
- FTHM 0.07
- MACD
- NXL -0.05
- FTHM 0.02
- Stochastic Oscillator
- NXL 0.01
- FTHM 94.74
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.